Thorsten Poehl, new CEO of Boehringer Ingelheim Spain
Poehl, with an excellent career at this multinational pharmaceutical corporation since 1993, has headed up subsidiaries in Ecuador, Norway and Mexico.
By Biocat
Thorsten Poehl has been named CEO of Boehringer Ingelheim Spain, based in Sant Cugat del Vallès (Barcelona), taking over for Albert Ros who has taken charge of the prescription medicine division for Japan, the United States, Australia, New Zealand and Canada.
Poehl holds a degree in Business Administration and Economics from the University of Munster (Germany) and the University of Pau and Pays de l'Adour (France). In 1992, he began his career as an International Product Manager at B. Braun Aesculap and in 1993 joined Boehringer Ingelheim in the marketing department for Germany and Brazil. He continued to move up in the company, holding positions including general manager of the Boehringer Ingelheim subsidiaries in Ecuador, Norway and Mexico. In mid-2010 he took over as division head for global talent management in the corporate headquarters in Germany.
Boehringer Ingelheim came to Spain in 1952 and over these years has positioned itself among the top ten pharmaceutical companies in the country. The company has two international centers in Sant Cugat del Vallès (pharmaceutical production plant) and Malgrat de Mar (chemical production plant) and more than 1,600 workers.
On a global level, Boehringer Ingelheim aims to launch a new lung-cancer drug to market this year. Alongside diabetes, oncology is the second medical pillar of this company.